利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

33 条记录 (耗时 0.02 秒)

    Human monoclonal antibodies derived from human B cells and having neutralizing activity against influenza A viruses
    1.
    发明授权
    Human monoclonal antibodies derived from human B cells and having neutralizing activity against influenza A viruses 有权
    来自人B细胞并具有针对甲型流感病毒的中和活性的人单克隆抗体

    公开(公告)号：US09573991B2

    公开(公告)日：2017-02-21

    申请号：US13583529

    申请日：2011-03-07

    申请人： Shin Jae Chang ,  Jong Mook Kim ,  Kye Sook Yi ,  Hyun Joo Lee

    发明人： Shin Jae Chang ,  Jong Mook Kim ,  Kye Sook Yi ,  Hyun Joo Lee

    IPC分类号： C07K16/10 ,  A61K39/42 ,  G01N33/569 ,  A61K39/00

    CPC分类号： C07K16/1018 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/76 ,  C07K2317/92 ,  G01N33/56983 ,  G01N2333/11

    摘要： The present invention relates to human monoclonal antibodies derived from human B cells present in the blood of patients who had recovered from infection with influenza A viruses, wherein the monoclonal antibodies have neutralizing activity against influenza A viruses. The anti-influenza A virus monoclonal antibody of the present invention has binding and neutralizing activities against at least one influenza A virus selected from the group consisting of influenza A virus H1, H2 and H5 subtypes, and thus it is useful for the prevention and treatment of a disease caused by the influenza A virus and is also useful for diagnosis of influenza A virus infection.

    摘要翻译： 本发明涉及从甲型流感病毒感染中恢复的患者血液中存在的人B细胞的人单克隆抗体，其中所述单克隆抗体具有针对甲型流感病毒的中和活性。 本发明的抗A型流感病毒单克隆抗体对选自甲型流感病毒H1，H2和H5亚型的至少一种甲型流感病毒具有结合和中和活性，因此可用于预防和治疗 由甲型流感病毒引起的疾病，也可用于甲型流感病毒感染的诊断。

    High efficiency retroviral vectors that contain none of viral coding sequences
    5.
    发明授权
    High efficiency retroviral vectors that contain none of viral coding sequences 有权
    不含病毒编码序列的高效率逆转录病毒载体

    公开(公告)号：US06451595B1

    公开(公告)日：2002-09-17

    申请号：US09463067

    申请日：2000-01-14

    申请人： Sunyoung Kim ,  Seung Shin Yu ,  Jong-mook Kim

    发明人： Sunyoung Kim ,  Seung Shin Yu ,  Jong-mook Kim

    IPC分类号： C12N15867

    CPC分类号： C12N15/86 ,  C12N2740/13043 ,  C12N2830/42 ,  C12N2830/50 ,  C12N2840/203 ,  C12N2840/44

    摘要： The present invention relates to improved retroviral vectors for gene therapy. In this invention, retroviral vectors with higher safety and efficiency are constructed from MLV-based starting vectors, MON and MIN. The improved vectors have the following features: 1) sequences corresponding to MLV-derived pol gene are completely deleted in the vectors, avoiding homologous recombination which has been a baffling problem in conventional retroviral vectors, 2) a heterologous intron, splicing acceptor and/or non-coding sequence are/is inserted into the upstream position of a cloning site, maximizing the expression of a foreign gene through efficient splicing, 3) the vectors contain either the full-length U3 sequence of 5′ LTR or a strong heterologous promoter instead, permitting the abundant production of RNA, 4) either IRES (Internal Ribosomal Entry Site) or internal SV40 minimal promoter is inserted into the downstream position of cloning site, enabling the simultaneous expression of two or more foreign genes. Since the improved retroviral vectors of this invention turn out to be safe and to express the foreign gene efficiently, they are useful for gene therapy and the like.

    摘要翻译： 本发明涉及用于基因治疗的改良逆转录病毒载体。 在本发明中，具有更高安全性和效率的逆转录病毒载体由基于MLV的起始载体MON和MIN构建。 改进的载体具有以下特征：1）对应于MLV衍生的pol基因的序列在载体中完全缺失，避免了在常规逆转录病毒载体中已经成为障碍问题的同源重组，2）异源内含子，剪接受体和/或 非编码序列被插入到克隆位点的上游位置，通过有效剪接使外源基因的表达最大化，3）载体含有5'LTR的全长U3序列或者强异源启动子 ，允许大量产生RNA，4）将IRES（内部核糖体进入位点）或内部SV40最小启动子插入到克隆位点的下游位置，使得能够同时表达两个或多个外源基因。 由于本发明改良的逆转录病毒载体是安全的并有效表达外源基因，所以它们可用于基因治疗等。

    GENE THERAPY FOR DIABETIC NEUROPATHY USING AN HGF ISOFORM
    6.
    发明申请
    GENE THERAPY FOR DIABETIC NEUROPATHY USING AN HGF ISOFORM 有权
    使用HGF ISOFORM进行糖尿病神经病变的基因治疗

    公开(公告)号：US20140296142A1

    公开(公告)日：2014-10-02

    申请号：US14355792

    申请日：2012-03-27

    申请人： Jong Mook Kim ,  Jae Gyun Jeong

    发明人： Jong Mook Kim ,  Jae Gyun Jeong

    IPC分类号： C07K14/475

    CPC分类号： C07K14/4753 ,  A61K31/711 ,  A61K38/1833 ,  A61K48/005

    摘要： The present invention relates to a pharmaceutical composition for the prevention or treatment of diabetic neuropathy, wherein the pharmaceutical composition comprises, as active ingredients, different types of isoforms of HGF or a polynucleotide encoding the isoforms. The present invention is the first invention demonstrating that diabetic neuropathy can be prevented and treated using different types of isoforms of HGF. According to the present invention, it is possible to very effectively treat diabetic neuropathy.

    摘要翻译： 本发明涉及用于预防或治疗糖尿病性神经病的药物组合物，其中该药物组合物包含作为活性成分的不同类型的HGF同种型或编码同种型的多核苷酸。 本发明是第一个发现，可以使用不同类型的HGF异构体来预防和治疗糖尿病性神经病变。 根据本发明，可以非常有效地治疗糖尿病性神经病变。

    METHOD FOR SELECTING A HIGH EXPRESSION RECOMBINANT CELL LINE
    8.
    发明申请
    METHOD FOR SELECTING A HIGH EXPRESSION RECOMBINANT CELL LINE 有权
    选择高表达重组细胞系的方法

    公开(公告)号：US20120009682A1

    公开(公告)日：2012-01-12

    申请号：US13255004

    申请日：2010-03-30

    申请人： MyungSam Cho ,  Min Seok Chang ,  Jong-Mook Kim ,  HyunJoo Lee ,  Yoo Cheol Song ,  ManSu Kim

    发明人： MyungSam Cho ,  Min Seok Chang ,  Jong-Mook Kim ,  HyunJoo Lee ,  Yoo Cheol Song ,  ManSu Kim

    IPC分类号： C12N15/64 ,  C12N5/10 ,  C12N5/16 ,  C12N15/63

    CPC分类号： C12N15/65 ,  C12N15/1086 ,  C12N15/69 ,  C12N15/85 ,  C12N2800/24 ,  C12N2830/46 ,  C12N2830/50 ,  C12P21/02

    摘要： The present invention relates to a method of selecting high producer clones by using an expression vector, the expression vector comprising: (i) a gene expression cassette comprising a selectable marker gene to which polyA has been inoperably linked; and (ii) a gene expression cassette which encodes a recombinant protein of interest and to which polyA has been operably linked. According to the invention, high producer clones can be selected from cell populations at least 10 times fewer than in the existing methods of selecting cell lines. Particularly, high producer clones can be selected using a low concentration of MTX compared to a conventional stepwise gene amplification strategy which comprises carrying out multiple amplification steps while increasing the concentration of MTX. Accordingly, the development period of cell lines can be shortened and the labor and cost required for selection of high-productivity cell clones can be reduced, whereby more efficient production of proteins is possible even when general selectable marker genes other than MTX are used.

    摘要翻译： 本发明涉及通过使用表达载体选择高生产者克隆的方法，所述表达载体包含：（i）包含聚A不可操作连接的选择标记基因的基因表达盒; 和（ii）编码目的重组蛋白质并且polyA已被可操作地连接的基因表达盒。 根据本发明，可以从细胞群体中选择高生产者克隆比选择细胞系的现有方法的至少10倍。 特别地，与传统的逐步基因扩增策略相比，可以使用低浓度的MTX来选择高生产者克隆，其包括在增加MTX浓度的同时进行多个扩增步骤。 因此，可以缩短细胞系的发育期，并且可以降低选择高生产率细胞克隆所需的劳动力和成本，从而即使使用MTX以外的一般可选择标记基因，蛋白质的更高效生产也是可能的。

    Hybrid Hepatocyte Growth Factor Gene Having High Expression Efficiency of Two Heterotypes of Hepatocyte Growth Factor
    9.
    发明申请
    Hybrid Hepatocyte Growth Factor Gene Having High Expression Efficiency of Two Heterotypes of Hepatocyte Growth Factor 有权
    具有两种肝细胞生长因子异型表达效率的混合型肝细胞生长因子基因

    公开(公告)号：US20100105878A1

    公开(公告)日：2010-04-29

    申请号：US12650860

    申请日：2009-12-31

    申请人： Jong-Mook Kim ,  Woong Hahn ,  Eun-Jin Park

    发明人： Jong-Mook Kim ,  Woong Hahn ,  Eun-Jin Park

    IPC分类号： C07K14/475 ,  C12N5/02 ,  C12N1/20 ,  C12N1/19

    CPC分类号： C07K14/4753

    摘要： The present invention relates to a hybrid Hepatocyte Growth Factor (HGF) gene which is prepared by inserting an inherent or foreign intron between exons 4 and 5 in HGF cDNA, which has a base sequence of SEQ ID NO: 2. The gene has high expression efficiency and simultaneously expresses two heterotypes of HGF and dHGF (deleted variant HGF). Further the gene may be used for treating or preventing ischemic or liver diseases.

    摘要翻译： 本发明涉及通过在具有SEQ ID NO：2的碱基序列的HGF cDNA中插入外显子4和5之间的固有或外来内含子而制备的混合肝细胞生长因子（HGF）基因。该基因具有高表达 并且同时表达HGF和dHGF（缺失变体HGF）的两种异型。 此外，该基因可用于治疗或预防缺血性或肝脏疾病。

    Treatment and Prevention of Cardiac Conditions Using Two or More Isoforms of Hepatocyte Growth Factor
    10.
    发明申请
    Treatment and Prevention of Cardiac Conditions Using Two or More Isoforms of Hepatocyte Growth Factor 审中-公开
    使用两种或更多种肝细胞生长因子异构体治疗和预防心脏病症

    公开(公告)号：US20090202606A1

    公开(公告)日：2009-08-13

    申请号：US12359137

    申请日：2009-01-23

    申请人： Jong-Mook Kim ,  Sujeong Kim ,  Woong Hahn

    发明人： Jong-Mook Kim ,  Sujeong Kim ,  Woong Hahn

    IPC分类号： A61F2/00 ,  A61K38/16 ,  A61K31/7088

    CPC分类号： A61K38/1833 ,  A61K31/70

    摘要： The present invention relates to methods for treating or preventing cardiac conditions in a subject comprising administering to the subject two or more isoforms of hepatocyte growth factor (HGF). The present invention further relates to methods for promoting endothelial cell growth in a blood vessel comprising administering to the blood vessel two or more isoforms of hepatocyte growth factor (HGF). In one embodiment the two or more isoforms of HGF are administered as one or more polynucleotides encoding the isoforms.

    摘要翻译： 本发明涉及用于治疗或预防受试者心脏病症的方法，其包括向受试者施用两种或更多种肝细胞生长因子（HGF）的同种型。 本发明还涉及促进血管内皮细胞生长的方法，包括向血管施用两种或多种肝细胞生长因子（HGF）的同种型。 在一个实施方案中，HGF的两种或更多种同种型作为编码同种型的一种或多种多核苷酸给药。